Alliance Capital Management L.P. (AB) 23.44 $AB
AB Science announces the publication in the Journal of Neuroinflammation of preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis
GlobeNewswire - Mon Jul 11, 12:50AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces the publication of preclinical study results with masitinib in amyotrophic lateral sclerosis (ALS). Entitled, 'Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis' this article and its accompanying Online Supplementary Material are freely accessible online from the peer-reviewed scientific review Journal of Neuroinflammation: DOI:10.1186/s12974-016-0620-9; https://jneuroinflammation.biomedcentral.com/articles.
AB: 23.44 (-0.09)
AB Announces Agreement In Principle To Assume Management Of Visium Global Fund
PR Newswire - Fri Jun 17, 3:56PM CDT
AllianceBernstein L.P. ("AB"
, a leading global investment firm with $487 billion in assets under management, announced today that it has signed a letter of intent under which AB would assume management of Visium Asset Management's Global Fund, a multisector long/short equity hedge fund. As part of the transaction, the Visium Global Fund's investment team and certain support staff would join AB.
AB: 23.44 (-0.09)
AB Announces May 31, 2016 Assets Under Management
PR Newswire - Thu Jun 09, 3:24PM CDT
AllianceBernstein L.P. ("AB" and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today announced that preliminary assets under management increased to $487 billion during May 2016 from $483 billion at the end of April. Firmwide net inflows largely drove the 0.8% increase, though market appreciation contributed as well. The Institutions channel represented the largest share of total net inflows, followed by Retail and Private Wealth Management.
AB: 23.44 (-0.09)
AB Science will hold an Investor & Analyst conference on masitinib in Amyotrophic Lateral Sclerosis (ALS) in New York, USA, on June 13, 2016
GlobeNewswire - Wed Jun 08, 10:54AM CDT
Following recommendation by the European Medicines Agency (EMA) to file masitinib for conditional marketing authorization in Amyotrophic Lateral Sclerosis (ALS), AB Science is holding an Investor & Analyst conference in New York on June 13, 2016
AB: 23.44 (-0.09)
AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization
GlobeNewswire - Mon Jun 06, 12:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announced today that Rapporteurs appointed by the European Medicines Agency (EMA) have recommended the filing of masitinib in combination with riluzole in the treatment of adult patients with amyotrophic lateral sclerosis (ALS) for conditional marketing authorization.
AB: 23.44 (-0.09)
AB Science Will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21st Congress of the European Hematology Association
GlobeNewswire - Mon May 30, 12:57AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that results from its phase 3 trial in severe systemic mastocytosis will be presented as an oral presentation at the 21 Congress of the European Hematology Association (June 9 - 12, 2016, Copenhagen, Denmark).
AB: 23.44 (-0.09)
Lazard (LAZ) Hit by Economic Headwinds: Time to Sell?
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:19AM CDT
We have issued an updated research report on Lazard Ltd. (LAZ) on May 23. Shares of this asset manager recorded a year-to-date negative return of 20.4%.
AB: 23.44 (-0.09), LAZ: 31.64 (-0.45), AMG: 142.42 (-1.32), GBL: 33.89 (+0.01)
Affiliated Managers (AMG) is a Must-Add Now: Here's Why
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:17AM CDT
From recording 6-year (2010--2015) CAGR of 13.8% in assets under management to holding an almost unbeaten track record of buying equity interests in asset management companies with strong performance-oriented products, Affiliated Managers Group Inc. (AMG), has been firing on all cylinders of late.
APAM: 27.65 (-0.75), AB: 23.44 (-0.09), AMG: 142.42 (-1.32), GBL: 33.89 (+0.01)
Eaton Vance (EV) Q2 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 23, 5:31AM CDT
Will Eaton Vance (EV) disappoint yet again? Or will it surpass earnings estimates this quarter? Let's see how things have shaped up for this announcement.
AB: 23.44 (-0.09), AMG: 142.42 (-1.32), WAL: 33.97 (-0.14), EV: 36.82 (+0.18)
AB Announces April 30, 2016 Assets Under Management
PR Newswire - Tue May 10, 3:04PM CDT
AllianceBernstein L.P. ("AB" and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today announced that preliminary assets under management increased to $483 billion during April 2016 from $479 billion at the end of March. The 0.8% increase resulted from market appreciation, including the positive impact of foreign currency moves against the dollar, partially offset by firmwide net outflows. By channel, net flows were positive in Retail and negative in Institutions and Private Wealth Management.
AB: 23.44 (-0.09)
AllianceBernstein Has Returned 19.1% Since SmarTrend Recommendation (AB)
Comtex SmarTrend(R) - Wed May 04, 12:50AM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 19.12% as of today's recent price of $22.90.
AB: 23.44 (-0.09)
AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
GlobeNewswire - Mon May 02, 12:53AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the filing for registration to European Medicines Agency (EMA) for masitinib in the treatment of adult patient with severe systemic mastocytosisunresponsive to optimal symptomatic treatment, with date of review process starting on 26 April 2016. Masitinib is the first treatment to be evaluated in this indication. Top-line results from this phase 3 were previously announced on 30 November 2015.
AB: 23.44 (-0.09)
Choice Hotels International Signs Master Development Agreement To Enter Middle East
PR Newswire - Thu Apr 28, 8:26AM CDT
Choice Hotels International, Inc., one of the largest hotel companies in the world, announced today the signing of a master development agreement with Equinox Ventures Ltd, a joint venture between Equinox Group Ltd. and Al Tayyar Travel Group, to introduce and develop three of Choice's most prominent brands: Clarion, Comfort and Quality across the UAE and Saudi Arabia. This announcement, its fifth EMEA market portfolio expansion in the past six months, is part of Choice's strategy to continue to expand its brand internationally.
AB: 23.44 (-0.09), CHH: 48.20 (-0.23)
AllianceBernstein posts 1Q profit
Automated Insights - Thu Apr 28, 7:54AM CDT
NEW YORK (AP) _ AllianceBernstein Holding LP (AB) on Thursday reported first-quarter profit of $55.7 million.
AB: 23.44 (-0.09)
Uptrend Call Working As AllianceBernstein Stock Rises 27.0% (AB)
Comtex SmarTrend(R) - Tue Apr 26, 1:15PM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 27.05% as of today's recent price of $24.43.
AB: 23.44 (-0.09)
AB Successfully Closes a Second Commercial Real Estate Debt Fund and Aggregate Commitments Surpass $2.3 Billion
PR Newswire - Wed Apr 20, 10:19AM CDT
AllianceBernstein L.P. ("AB" , a leading global investment management firm, today announced the closing of its second commercial real estate debt fund with total commitments of $1.55 billion, surpassing its $1 billion target. AB's second fund ("Fund II" received commitments from a diverse range of global insurers, pensions, and foundations and closed at a size double the $750 million predecessor fund, AB Commercial Real Estate Debt Series I-B ("Fund I" . In connection with Fund II's closing, investors for Fund I also extended their commitment period which increased total commitments in AB's private commercial real estate credit platform to in excess of $2.3 billion.
AB: 23.44 (-0.09)
21.9% Return Seen to Date on SmarTrend AllianceBernstein Call (AB)
Comtex SmarTrend(R) - Tue Apr 19, 1:35AM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 21.87% as of today's recent price of $23.43.
AB: 23.44 (-0.09)
AB to Report First Quarter 2016 Results on Thursday, April 28, 2016
PR Newswire - Thu Apr 14, 12:23PM CDT
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that First Quarter 2016 financial and operating results will be released on Thursday, April 28, 2016. Management will conduct a teleconference call beginning at 8:00 am (ET), following the release of its financial results. The call will be hosted by Peter S. Kraus, Chairman and Chief Executive Officer, and John C. Weisenseel, Chief Financial Officer.
AB: 23.44 (-0.09)
AllianceBernstein, Equinix, Facebook, Etsy and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
AllianceBernstein, Equinix, Facebook, Etsy and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
VNET: 10.20 (+0.06), AB: 23.44 (-0.09), EQIX: 386.17 (-1.03), FB: 117.52 (-0.41), ETSY: 10.26 (+0.06)
AB Science announces the publication in the Journal of Neuroinflammation of preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis
GlobeNewswire - Mon Jul 11, 12:50AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces the publication of preclinical study results with masitinib in amyotrophic lateral sclerosis (ALS). Entitled, 'Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis' this article and its accompanying Online Supplementary Material are freely accessible online from the peer-reviewed scientific review Journal of Neuroinflammation: DOI:10.1186/s12974-016-0620-9; https://jneuroinflammation.biomedcentral.com/articles.
AB: 23.44 (-0.09)
AB Announces Agreement In Principle To Assume Management Of Visium Global Fund
PR Newswire - Fri Jun 17, 3:56PM CDT
AllianceBernstein L.P. ("AB"
, a leading global investment firm with $487 billion in assets under management, announced today that it has signed a letter of intent under which AB would assume management of Visium Asset Management's Global Fund, a multisector long/short equity hedge fund. As part of the transaction, the Visium Global Fund's investment team and certain support staff would join AB. AB: 23.44 (-0.09)
AB Announces May 31, 2016 Assets Under Management
PR Newswire - Thu Jun 09, 3:24PM CDT
AllianceBernstein L.P. ("AB"
and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today announced that preliminary assets under management increased to $487 billion during May 2016 from $483 billion at the end of April. Firmwide net inflows largely drove the 0.8% increase, though market appreciation contributed as well. The Institutions channel represented the largest share of total net inflows, followed by Retail and Private Wealth Management. AB: 23.44 (-0.09)
AB Science will hold an Investor & Analyst conference on masitinib in Amyotrophic Lateral Sclerosis (ALS) in New York, USA, on June 13, 2016
GlobeNewswire - Wed Jun 08, 10:54AM CDT
Following recommendation by the European Medicines Agency (EMA) to file masitinib for conditional marketing authorization in Amyotrophic Lateral Sclerosis (ALS), AB Science is holding an Investor & Analyst conference in New York on June 13, 2016
AB: 23.44 (-0.09)
AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization
GlobeNewswire - Mon Jun 06, 12:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announced today that Rapporteurs appointed by the European Medicines Agency (EMA) have recommended the filing of masitinib in combination with riluzole in the treatment of adult patients with amyotrophic lateral sclerosis (ALS) for conditional marketing authorization.
AB: 23.44 (-0.09)
AB Science Will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21st Congress of the European Hematology Association
GlobeNewswire - Mon May 30, 12:57AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that results from its phase 3 trial in severe systemic mastocytosis will be presented as an oral presentation at the 21 Congress of the European Hematology Association (June 9 - 12, 2016, Copenhagen, Denmark).
AB: 23.44 (-0.09)
Lazard (LAZ) Hit by Economic Headwinds: Time to Sell?
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:19AM CDT
We have issued an updated research report on Lazard Ltd. (LAZ) on May 23. Shares of this asset manager recorded a year-to-date negative return of 20.4%.
AB: 23.44 (-0.09), LAZ: 31.64 (-0.45), AMG: 142.42 (-1.32), GBL: 33.89 (+0.01)
Affiliated Managers (AMG) is a Must-Add Now: Here's Why
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:17AM CDT
From recording 6-year (2010--2015) CAGR of 13.8% in assets under management to holding an almost unbeaten track record of buying equity interests in asset management companies with strong performance-oriented products, Affiliated Managers Group Inc. (AMG), has been firing on all cylinders of late.
APAM: 27.65 (-0.75), AB: 23.44 (-0.09), AMG: 142.42 (-1.32), GBL: 33.89 (+0.01)
Eaton Vance (EV) Q2 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 23, 5:31AM CDT
Will Eaton Vance (EV) disappoint yet again? Or will it surpass earnings estimates this quarter? Let's see how things have shaped up for this announcement.
AB: 23.44 (-0.09), AMG: 142.42 (-1.32), WAL: 33.97 (-0.14), EV: 36.82 (+0.18)
AB Announces April 30, 2016 Assets Under Management
PR Newswire - Tue May 10, 3:04PM CDT
AllianceBernstein L.P. ("AB"
and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today announced that preliminary assets under management increased to $483 billion during April 2016 from $479 billion at the end of March. The 0.8% increase resulted from market appreciation, including the positive impact of foreign currency moves against the dollar, partially offset by firmwide net outflows. By channel, net flows were positive in Retail and negative in Institutions and Private Wealth Management. AB: 23.44 (-0.09)
AllianceBernstein Has Returned 19.1% Since SmarTrend Recommendation (AB)
Comtex SmarTrend(R) - Wed May 04, 12:50AM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 19.12% as of today's recent price of $22.90.
AB: 23.44 (-0.09)
AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
GlobeNewswire - Mon May 02, 12:53AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the filing for registration to European Medicines Agency (EMA) for masitinib in the treatment of adult patient with severe systemic mastocytosisunresponsive to optimal symptomatic treatment, with date of review process starting on 26 April 2016. Masitinib is the first treatment to be evaluated in this indication. Top-line results from this phase 3 were previously announced on 30 November 2015.
AB: 23.44 (-0.09)
Choice Hotels International Signs Master Development Agreement To Enter Middle East
PR Newswire - Thu Apr 28, 8:26AM CDT
Choice Hotels International, Inc., one of the largest hotel companies in the world, announced today the signing of a master development agreement with Equinox Ventures Ltd, a joint venture between Equinox Group Ltd. and Al Tayyar Travel Group, to introduce and develop three of Choice's most prominent brands: Clarion, Comfort and Quality across the UAE and Saudi Arabia. This announcement, its fifth EMEA market portfolio expansion in the past six months, is part of Choice's strategy to continue to expand its brand internationally.
AB: 23.44 (-0.09), CHH: 48.20 (-0.23)
AllianceBernstein posts 1Q profit
Automated Insights - Thu Apr 28, 7:54AM CDT
NEW YORK (AP) _ AllianceBernstein Holding LP (AB) on Thursday reported first-quarter profit of $55.7 million.
AB: 23.44 (-0.09)
Uptrend Call Working As AllianceBernstein Stock Rises 27.0% (AB)
Comtex SmarTrend(R) - Tue Apr 26, 1:15PM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 27.05% as of today's recent price of $24.43.
AB: 23.44 (-0.09)
AB Successfully Closes a Second Commercial Real Estate Debt Fund and Aggregate Commitments Surpass $2.3 Billion
PR Newswire - Wed Apr 20, 10:19AM CDT
AllianceBernstein L.P. ("AB"
, a leading global investment management firm, today announced the closing of its second commercial real estate debt fund with total commitments of $1.55 billion, surpassing its $1 billion target. AB's second fund ("Fund II" received commitments from a diverse range of global insurers, pensions, and foundations and closed at a size double the $750 million predecessor fund, AB Commercial Real Estate Debt Series I-B ("Fund I" . In connection with Fund II's closing, investors for Fund I also extended their commitment period which increased total commitments in AB's private commercial real estate credit platform to in excess of $2.3 billion. AB: 23.44 (-0.09)
21.9% Return Seen to Date on SmarTrend AllianceBernstein Call (AB)
Comtex SmarTrend(R) - Tue Apr 19, 1:35AM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 21.87% as of today's recent price of $23.43.
AB: 23.44 (-0.09)
AB to Report First Quarter 2016 Results on Thursday, April 28, 2016
PR Newswire - Thu Apr 14, 12:23PM CDT
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that First Quarter 2016 financial and operating results will be released on Thursday, April 28, 2016. Management will conduct a teleconference call beginning at 8:00 am (ET), following the release of its financial results. The call will be hosted by Peter S. Kraus, Chairman and Chief Executive Officer, and John C. Weisenseel, Chief Financial Officer.
AB: 23.44 (-0.09)
AllianceBernstein, Equinix, Facebook, Etsy and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
AllianceBernstein, Equinix, Facebook, Etsy and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
VNET: 10.20 (+0.06), AB: 23.44 (-0.09), EQIX: 386.17 (-1.03), FB: 117.52 (-0.41), ETSY: 10.26 (+0.06)
